Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/is-trail-the-holy-grail-of-cancer-therapy-pd1HHpJoGu
References (174)
-
R. Koschny, H. Holland, J. Sykora, T. Haas, M. Sprick, T. Ganten, W. Krupp, M. Bauer, P. Ahnert, J. Meixensberger, H. Walczak (2007)
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced ApoptosisClinical Cancer Research, 13
-
P. Horák, D. Pils, A. Kaider, A. Pinter, K. Elandt, C. Sax, C. Zielinski, R. Horvat, R. Zeillinger, A. Reinthaller, M. Krainer (2005)
Perturbation of the Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Cascade in Ovarian Cancer: Overexpression of FLIPL and Deregulation of the Functional Receptors DR4 and DR5Clinical Cancer Research, 11
-
D. Daniel, Becky Yang, D. Lawrence, K. Totpal, I. Balter, Wyne Lee, Alvin Gogineni, M. Cole, S. Yee, S. Ross, A. Ashkenazi (2007)
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.Blood, 110 12
-
Alexander Golks, D. Brenner, C. Fritsch, P. Krammer, I. Lavrik (2005)
c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis*Journal of Biological Chemistry, 280
-
Jerry Adams, S. Cory (2007)
The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 26
-
A. Younes, J. Vose, A. Zelenetz, Mitchell Smith, H. Burris, S. Ansell, J. Klein, E. Kumm, M. Czuczman (2005)
Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).Blood, 106
-
C. Oldenhuis, C. Mom, S. Sleijfer, J. Gietema, N. Fox, A. Corey, F. Eskens, W. Loos, E. Vries, J. Verweij (2008)
A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatinJournal of Clinical Oncology, 26
-
G. Screaton, J. Mongkolsapaya, Xiao-ning Xu, A. Cowper, A. McMichael, J. Bell (1997)
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAILCurrent Biology, 7
-
N. Mitsiades, C. Mitsiades, V. Poulaki, D. Chauhan, P. Richardson, T. Hideshima, N. Munshi, S. Treon, K. Anderson (2002)
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.Blood, 99 11
-
M. Degli-Esposti, P. Smolak, H. Walczak, Jennifer Waugh, Changwei Huang, R. Dubose, R. Goodwin, Craig Smith (1997)
Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor FamilyThe Journal of Experimental Medicine, 186
-
P. Horák, D. Pils, Griet Haller, I. Pribill, M. Roessler, S. Tomek, R. Horvat, R. Zeillinger, C. Zielinski, M. Krainer (2005)
Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian CancerMolecular Cancer Research, 3
-
S. Shankar, Xufen Chen, R. Srivastava (2005)
Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivoThe Prostate, 62
-
S. Ray, A. Almasan (2003)
Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.Cancer research, 63 15
-
A. Chuntharapai, Kelly Dodge, K. Grimmer, K. Schroeder, S. Marsters, H. Koeppen, A. Ashkenazi, K. Kim (2001)
Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4The Journal of Immunology, 166
-
F. Kischkel, D. Lawrence, A. Tinel, Heidi Leblanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Arnott, A. Ashkenazi (2001)
Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8*The Journal of Biological Chemistry, 276
-
D. Buchsbaum, T. Zhou, W. Grizzle, P. Oliver, C. Hammond, Sijian Zhang, M. Carpenter, A. Lobuglio (2003)
Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 10 Pt 1
-
M. Sheikh, Ying Huang, Ester Fernandez-Salas, W. El-Deiry, H. Friess, S. Amundson, Jing Yin, Stephen Meltzer, Nikki Holbrook, A. Fornace (1999)
The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tractOncogene, 18
-
A. Nebbioso, N. Clarke, E. Voltz, E. Germain, C. Ambrosino, P. Bontempo, R. Álvarez, E. Schiavone, F. Ferrara, F. Bresciani, A. Weisz, A. Lera, H. Gronemeyer, L. Altucci (2005)
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cellsNature Medicine, 11
-
N. Waterhouse, J. Ricci, D. Green (2002)
And all of a sudden it's over: mitochondrial outer-membrane permeabilization in apoptosis.Biochimie, 84 2-3
-
Yihua Huang, Miao Lu, Hao Wu (2004)
Antagonizing XIAP-mediated caspase-3 inhibition. Achilles' heel of cancers?Cancer cell, 5 1
-
E. Bremer, J. Kuijlen, D. Samplonius, H. Walczak, L. Leij, W. Helfrich (2004)
Target cell‐restricted and ‐enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2International Journal of Cancer, 109
-
M. Sprick, E. Rieser, H. Stahl, A. Grosse‐Wilde, M. Weigand, H. Walczak (2002)
Caspase‐10 is recruited to and activated at the native TRAIL and CD95 death‐inducing signalling complexes in a FADD‐dependent manner but can not functionally substitute caspase‐8The EMBO Journal, 21
-
M. Shrader, M. Pino, L. Lashinger, M. Bar‐eli, L. Adam, C. Dinney, D. McConkey (2007)
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.Cancer research, 67 4
-
M. Leverkus, M. Sprick, T. Wachter, T. Mengling, B. Baumann, E. Serfling, E. Bröcker, M. Goebeler, M. Neumann, H. Walczak (2003)
Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase MaturationMolecular and Cellular Biology, 23
-
Jürgen Held, K. Schulze-Osthoff (2001)
Potential and caveats of TRAIL in cancer therapy.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 4 4
-
D. Lawrence, Z. Shahrokh, S. Marsters, Kirsten Achilles, Danny Shih, B. Mounho, K. Hillan, K. Totpal, L. Deforge, P. Schow, J. Hooley, S. Sherwood, R. Pai, Susan Leung, L. Khan, B. Gliniak, J. Bussiere, Craig Smith, S. Strom, S. Kelley, Judith Fox, Deborah Thomas, A. Ashkenazi (2001)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versionsNature Medicine, 7
-
H. Ehrhardt, S. Fulda, I. Schmid, J. Hiscott, K. Debatin, I. Jeremias (2003)
TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κBOncogene, 22
-
P. Clarke, K. Tyler (2006)
Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosisApoptosis, 12
-
R. Plummer, G. Attard, S. Pacey, Louise Li, A. Razak, R. Perrett, M. Barrett, I. Judson, S. Kaye, N. Fox, W. Halpern, A. Corey, H. Calvert, J. Bono (2007)
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced CancersClinical Cancer Research, 13
-
Y. Zeng, X. Wu, Michele Fiscella, Osamu Shimada, Robin Humphreys, V. Albert, Yoshiyuki Kakehi (2006)
Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.International journal of oncology, 28 2
-
M. Clayer, S. Bouralexis, A. Evdokiou, S. Hay, G. Atkins, David Findlay (2001)
Enhanced Apoptosis of Soft Tissue Sarcoma Cells with Chemotherapy: A Potential New Approach Using TrailJournal of Orthopaedic Surgery, 9
-
J. Stieglmaier, E. Bremer, C. Kellner, T. Liebig, B. Cate, M. Peipp, H. Schulze-Koops, M. Pfeiffer, H. Bühring, J. Greil, F. Oduncu, B. Emmerich, G. Fey, W. Helfrich (2008)
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion proteinCancer Immunology, Immunotherapy, 57
-
R. Nam, A. Toi, L. Klotz, J. Trachtenberg, M. Jewett, S. Appu, D. Loblaw, L. Sugar, S. Narod, M. Kattan (2007)
Assessing individual risk for prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 24
-
B. Barnhart, Elizabeth Alappat, M. Peter (2003)
The CD95 type I/type II model.Seminars in immunology, 15 3
-
U. Vilimanovich, V. Bumbasirevic (2008)
TRAIL induces proliferation of human glioma cells by c-FLIPL-mediated activation of ERK1/2Cellular and Molecular Life Sciences, 65
-
GE Diehl, HH Yue, K Hsieh (2004)
TRAIL-R as a negative regulator of innate immune cell responsesImmunity, 21
-
N. Harper, S. Farrow, A. Kaptein, G. Cohen, M. MacFarlane (2001)
Modulation of Tumor Necrosis Factor Apoptosis-inducing Ligand- induced NF-κB Activation by Inhibition of Apical Caspases*The Journal of Biological Chemistry, 276
-
P. Makhov, K. Golovine, Robert Uzzo, J. Rothman, P. Crispen, Tavis Shaw, B. Scoll, V. Kolenko (2008)
Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosisCell Death and Differentiation, 15
-
Xiao-Ming Yin (2006)
Bid, a BH3-only multi-functional molecule, is at the cross road of life and death.Gene, 369
-
D Hanahan, RA Weinberg (2000)
The hallmarks of cancerCell, 100
-
A. Patnaik, H. Wakelee, M. Mita, A. Fitzgerald, M. Hill, N. Fox, T. Howard, S. Ullrich, A. Tolcher, B. Sikic (2006)
HGS-ETR2-A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
L. Pukac, P. Kanakaraj, R. Humphreys, R. Alderson, M. Bloom, C. Sung, T. Riccobene, R. Johnson, M. Fiscella, Angela Mahoney, J. Carrell, Ernest Boyd, X. Yao, Linyi Zhang, L. Zhong, A. Kerczek, Lindsey Shepard, T. Vaughan, B. Edwards, C. Dobson, T. Salcedo, V. Albert (2005)
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBritish Journal of Cancer, 92
-
F. Kischkel, S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P. Krammer, M. Peter (1995)
Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor.The EMBO Journal, 14
-
N. Ishimura, H. Isomoto, S. Bronk, G. Gores (2006)
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells.American journal of physiology. Gastrointestinal and liver physiology, 290 1
-
Roy Herbst, D. Mendolson, S. Ebbinghaus, Michael Gordon, Peter O'Dwyer, G. Lieberman, J. Ing, R. Kurzrock, William Novotny, Gail Eckhardt (2006)
A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
P. Secchiero, E. Melloni, F. Corallini, A. Beltrami, F. Alviano, D. Milani, F. D'Aurizio, M. Iasio, D. Cesselli, G. Bagnara, G. Zauli (2008)
Tumor Necrosis Factor‐Related Apoptosis‐Inducing Ligand Promotes Migration of Human Bone Marrow Multipotent Stromal CellsSTEM CELLS, 26
-
T. Sayers, A. Brooks, C. Koh, Weihong Ma, N. Seki, A. Raziuddin, B. Blazar, Xia Zhang, P. Elliott, W. Murphy (2003)
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.Blood, 102 1
-
K. Takeda, N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa, Jane Tanner, T. Sayers, N. Seki, K. Okumura, H. Yagita, M. Smyth (2004)
Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody TherapyThe Journal of Experimental Medicine, 199
-
M. Thome, P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Mattmann, K. Burns, J. Bodmer, M. Schröter, C. Scaffidi, P. Krammer, M. Peter, J. Tschopp (1997)
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptorsNature, 386
-
M. Vogler, H. Walczak, Dominic Stadel, T. Haas, F. Genze, M. Jovanovic, J. Gschwend, T. Simmet, K. Debatin, S. Fulda (2008)
Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.Cancer research, 68 19
-
R. Koschny, T. Ganten, J. Sykora, T. Haas, M. Sprick, A. Kolb, W. Stremmel, H. Walczak (2007)
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic windowHepatology, 45
-
L. Chow, S. Eckhardt, D. Gustafson, C. O’Bryant, S. Hariharan, S. Diab, N. Fox, A. Corey, K. Padavic, M. Brown, R. Cohen (2006)
HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
M. Sprick, M. Weigand, M. Weigand, E. Rieser, C. Rauch, P. Juo, J. Blenis, P. Krammer, H. Walczak (2000)
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2.Immunity, 12 6
-
H. Walczak, M. Degli-Esposti, Richard Johnson, P. Smolak, Jennifer Waugh, N. Boiani, Martin Timour, M. Gerhart, K. Schooley, Craig Smith, R. Goodwin, C. Rauch (1997)
TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAILThe EMBO Journal, 16
-
D. Siegmund, P. Hadwiger, K. Pfizenmaier, H. Vornlocher, H. Wajant (2002)
Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced ApoptosisMolecular Medicine, 8
-
J. Sträter, U. Hinz, H. Walczak, G. Mechtersheimer, K. Koretz, C. Herfarth, P. Möller, T. Lehnert (2002)
Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 12
-
H. Stennicke, J. Jürgensmeier, H. Shin, Q. Deveraux, B. Wolf, X. Yang, Q. Zhou, H. Ellerby, L. Ellerby, D. Bredesen, D. Green, John Reed, C. Froelich, G. Salvesen (1998)
Pro-caspase-3 Is a Major Physiologic Target of Caspase-8*The Journal of Biological Chemistry, 273
-
A. Natoni, M. MacFarlane, S. Inoue, R. Walewska, A. Majid, D. Knee, D. Stover, M. Dyer, G. Cohen (2007)
TRAIL signals to apoptosis in CLL cells primarily through TRAIL R-1 whereas cross-linked agonistic TRAIL R-2 antibodies facilitate signalling via TRAIL R-2 -
F. Guo, C. Sigua, J. Tao, P. Bali, P. George, Yunqing Li, S. Wittmann, L. Moscinski, P. Atadja, K. Bhalla (2004)
Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia CellsCancer Research, 64
-
J. Vince, W. Wong, N. Khan, R. Feltham, Diep Chau, Afsar Ahmed, C. Benetatos, S. Chunduru, S. Condon, M. Mckinlay, R. Brink, M. Leverkus, V. Tergaonkar, P. Schneider, B. Callus, Frank Koentgen, D. Vaux, J. Silke (2007)
IAP Antagonists Target cIAP1 to Induce TNFα-Dependent ApoptosisCell, 131
-
Yang Pan, R. Xu, M. Peach, Huang Cp, D. Branstetter, B. Durbin, R. Herbst, G. Eckhardt, D. Mendelson, P. Holland (2007)
Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumorsJournal of Clinical Oncology, 25
-
L. Lê, H. Hirte, S. Hotte, M. Maclean, A. Iacobucci, A. Corey, N. Fox, A. Oza (2004)
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
-
Jianke Zhang, D. Cado, Ann Chen, N. Kabra, A. Winoto (1998)
Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1Nature, 392
-
A. Frew, A. Frew, R. Lindemann, B. Martin, C. Clarke, Janelle Sharkey, Desiree Anthony, K. Banks, N. Haynes, P. Gangatirkar, Kym Stanley, Jessica Bolden, K. Takeda, H. Yagita, J. Secrist, M. Smyth, M. Smyth, R. Johnstone, R. Johnstone (2008)
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonistProceedings of the National Academy of Sciences, 105
-
S. Vitovski, Jennifer Phillips, J. Sayers, P. Croucher (2007)
Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.The Journal of biological chemistry, 282 43
-
S. Hotte, H. Hirte, E. Chen, L. Siu, L. Lê, A. Corey, A. Iacobucci, M. Maclean, Larry Lo, N. Fox, A. Oza (2008)
A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid MalignanciesClinical Cancer Research, 14
-
J. Sheridan, S. Marsters, R. Pitti, A. Gurney, M. Skubatch, Daryl Baldwin, Lakshmi Ramakrishnan, C. Gray, K. Baker, W. Wood, A. Goddard, P. Godowski, A. Ashkenazi (1997)
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.Science, 277 5327
-
R. Herbst, D. Bajorin, H. Bleiberg, D. Blum, D. Hao, B. Johnson, R. Ozols, G. Demetri, P. Ganz, M. Kris, B. Levin, M. Markman, D. Raghavan, G. Reaman, R. Sawaya, L. Schuchter, J. Sweetenham, L. Vahdat, E. Vokes, R. Winn, R. Mayer (2006)
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 1
-
E. Varfolomeev, J. Blankenship, S. Wayson, A. Fedorova, N. Kayagaki, Parie Garg, K. Zobel, Jasmin Dynek, L. Elliott, H. Wallweber, J. Flygare, W. Fairbrother, K. Deshayes, V. Dixit, D. Vučić (2007)
IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent ApoptosisCell, 131
-
B. Sikic, H. Wakelee, M. Mehren, N. Lewis, A. Calvert, E. Plummer, N. Fox, T. Howard, Suzanne Jones, H. Burris (2007)
A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRIJournal of Clinical Oncology, 25
-
H Li, X Lin (2008)
Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activationCytokine, 41
-
O. Ndozangue-Touriguine, Michael Sebbagh, Delphine Mérino, Olivier Micheau, Jacques Bertoglio, J. Bréard (2008)
A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinomaOncogene, 27
-
E. Bremer, D. Samplonius, B. Kroesen, Linda Genne, Lou Leij, W. Helfrich (2004)
Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.Neoplasia, 6 5
-
Pascal Schneider (2000)
Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins.Methods in enzymology, 322
-
D. Buchsbaum, T. Zhou, A. Lobuglio (2006)
TRAIL receptor-targeted therapy.Future oncology, 2 4
-
Tomoyasu Uno, K. Takeda, Y. Kojima, H. Yoshizawa, H. Akiba, R. Mittler, F. Gejyo, K. Okumura, H. Yagita, M. Smyth (2006)
Eradication of established tumors in mice by a combination antibody-based therapyNature Medicine, 12
-
G. Jönsson, S. Paulie, A. Grandien (2003)
High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells.Anticancer research, 23 2B
-
S. Fulda, E. Meyer, K. Debatin (2002)
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpressionOncogene, 21
-
P. Schneider, D. Olson, A. Tardivel, B. Browning, A. Lugovskoy, Dahai Gong, M. Dobles, S. Hertig, K. Hofmann, H. Vlijmen, Y. Hsu, L. Burkly, J. Tschopp, T. Zheng (2003)
Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)*The Journal of Biological Chemistry, 278
-
P. Secchiero, Carlotta Zerbinati, E. Rimondi, F. Corallini, D. Milani, Vittorio Grill, G. Forti, Silvano Capitani, G. Zauli (2004)
TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cellsCellular and Molecular Life Sciences, 61
-
S. Hopkins‐Donaldson, J. Bodmer, K. Bourloud, C. Brognara, J. Tschopp, N. Gross (2000)
Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.Cancer research, 60 16
-
M. Irmler, M. Thome, M. Hahne, P. Schneider, K. Hofmann, Véronique Steiner, J. Bodmer, M. Schröter, K. Burns, C. Mattmann, D. Rimoldi, L. French, J. Tschopp (1997)
Inhibition of death receptor signals by cellular FLIPNature, 388
-
E. Bremer, D. Samplonius, M. Peipp, Linda Genne, B. Kroesen, G. Fey, M. Gramatzki, L. Leij, W. Helfrich (2005)
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.Cancer research, 65 8
-
K. Ichikawa, Weimin Liu, Limin Zhao, Z. Wang, Di Liu, Toshiaki Ohtsuka, Huan-zhu Zhang, J. Mountz, W. Koopman, R. Kimberly, T. Zhou (2001)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicityNature Medicine, 7
-
R. Ravi, Gauri Bedi, L. Engstrom, Qi Zeng, B. Mookerjee, C. Gélinas, E. Fuchs, A. Bedi (2001)
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κBNature Cell Biology, 3
-
K. Kim, Jae-Joon Song, J. An, Y. Kwon, Yong Lee (2005)
Pretreatment of Acetylsalicylic Acid Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Down-regulating BCL-2 Gene Expression*Journal of Biological Chemistry, 280
-
Gen Wu, T. Burns, Yi Zhan, E. Alnemri, W. El-Deiry (1999)
Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.Cancer research, 59 12
-
Gen Wu, T. Burns, E. McDonald, Wen Jiang, Ray Meng, I. Krantz, G. Kao, Dai-Di Gan, Junhao Zhou, R. Muschel, Stanley Hamilton, N. Spinner, S. Markowitz, Gary Wu, W. El-Deiry (1997)
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor geneNature Genetics, 17
-
S. Shamimi-Noori, W-S Yeow, M. Ziauddin, H. Xin, T. Tran, J. Xie, A. Loehfelm, P. Patel, J. Yang, D. Schrump, B. Fang, D. Nguyen (2008)
Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathwayCancer Gene Therapy, 15
-
A. Shanker, A. Brooks, Carlos Tristan, J. Wine, P. Elliott, H. Yagita, K. Takeda, M. Smyth, W. Murphy, T. Sayers (2008)
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.Journal of the National Cancer Institute, 100 9
-
W. Hallett, Erik Ames, Milad Motarjemi, I. Barão, A. Shanker, D. Tamang, T. Sayers, D. Hudig, W. Murphy (2008)
Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition1The Journal of Immunology, 180
-
R. Pitti, S. Marsters, S. Ruppert, C. Donahue, A. Moore, A. Ashkenazi (1996)
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*The Journal of Biological Chemistry, 271
-
M. Todaro, Y. Lombardo, M. Francipane, M. Alea, P. Cammareri, F. Iovino, A. Stefano, C. Bernardo, A. Agrusa, G. Condorelli, H. Walczak, G. Stassi (2008)
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4Cell Death and Differentiation, 15
-
L. Pritzker, M. Scatena, C. Giachelli (2004)
The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival.Molecular biology of the cell, 15 6
-
A. Şanlioğlu, A. Korcum, E. Pestereli, G. Erdogan, S. Karaveli, B. Savaş, T. Griffith, S. Sanlioglu (2007)
TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.International journal of radiation oncology, biology, physics, 69 3
-
Y. Gazitt (1999)
TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cellsLeukemia, 13
-
G. Zauli, E. Rimondi, V. Nicolin, E. Melloni, C. Celeghini, P. Secchiero (2004)
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.Blood, 104 7
-
H Wajant (2004)
TRAIL and NFkappaB signaling—a complex relationshipVitam Horm, 67
-
M. MacFarlane, S. Inoue, S. Kohlhaas, A. Majid, N. Harper, D. Kennedy, M. Dyer, M. Dyer, Gerry Cohen (2005)
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1Cell Death and Differentiation, 12
-
A. Natoni, M. MacFarlane, S. Inoue, R. Walewska, A. Majid, D. Knee, D. Stover, M. Dyer, G. Cohen (2007)
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL‐R1 whereas cross‐linked agonistic TRAIL‐R2 antibodies facilitate signalling via TRAIL‐R2British Journal of Haematology, 139
-
Heidi Leblanc, A. Ashkenazi (2003)
Apo2L/TRAIL and its death and decoy receptorsCell Death and Differentiation, 10
-
O. Micheau, M. Thome, P. Schneider, N. Holler, J. Tschopp, D. Nicholson, C. Briand, M. Grütter (2002)
The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex*The Journal of Biological Chemistry, 277
-
A. Yada, M. Yazawa, S. Ishida, H. Yoshida, K. Ichikawa, S. Kurakata, K. Fujiwara (2008)
A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes.Annals of oncology : official journal of the European Society for Medical Oncology, 19 6
-
O. Micheau, D. Merino (2004)
Controlling TRAIL-mediated caspase-3 activationLeukemia, 18
-
A. El-Zawahry, J. McKillop, C. Voelkel-Johnson (2005)
Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenograftsBMC Cancer, 5
-
H. Wajant (2004)
TRAIL and NFκB Signaling—a Complex RelationshipVitamins and Hormones Series, 67
-
T. Ganten, R. Koschny, J. Sykora, H. Schulze‐Bergkamen, P. Büchler, T. Haas, M. Schader, A. Untergasser, W. Stremmel, H. Walczak (2006)
Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic DrugsClinical Cancer Research, 12
-
M. McCarthy, M. Sznol, K. Divito, R. Camp, D. Rimm, H. Kluger (2005)
Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast CancerClinical Cancer Research, 11
-
H Wu, J Tschopp, SC Lin (2007)
Smac mimetics and TNFalpha: a dangerous liaison?Cell, 131
-
P. Geserick, C. Drewniok, M. Hupe, Tobias Haas, P. Diessenbacher, M. Sprick, Margarete Schön, Frank Henkler, Harald Gollnick, Henning Walczak, M. Leverkus (2008)
Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosisOncogene, 27
-
K. Clodi, Doris Wimmer, Yang Li, R. Goodwin, U. Jaeger, G. Mann, H. Gadner, A. Younes (2000)
Expression of tumour necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) receptors and sensitivity to TRAIL‐induced apoptosis in primary B‐cell acute lymphoblastic leukaemia cellsBritish Journal of Haematology, 111
-
E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. Peschon, M. Smyth (2002)
Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1The Journal of Immunology, 168
-
G. Gores, S. Kaufmann (2001)
Is TRAIL hepatotoxic?Hepatology, 34
-
L. Yee, M. Fanale, K. Dimick, S. Calvert, C. Robins, J. Ing, W. Novotny, A. Ashkenazi, H. Burris (2007)
A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphomaJournal of Clinical Oncology, 25
-
E. Toni, Susanne Thieme, A. Herbst, A. Behrens, P. Stieber, A. Jung, H. Blum, B. Göke, F. Kolligs (2008)
OPG Is Regulated by β-Catenin and Mediates Resistance to TRAIL-Induced Apoptosis in Colon CancerClinical Cancer Research, 14
-
S. Inoue, Marion MacFarlane, N. Harper, Luise Wheat, Martin Dyer, Gerald Cohen (2004)
Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignanciesCell Death and Differentiation, 11
-
T. Ganten, T. Haas, J. Sykora, H. Stahl, M. Sprick, S. Fas, A. Krueger, M. Weigand, A. Grosse‐Wilde, W. Stremmel, P. Krammer, H. Walczak (2004)
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugsCell Death and Differentiation, 11
-
K. Takeda, Y. Kojima, K. Ikejima, K. Harada, S. Yamashina, K. Okumura, Tomonori Aoyama, S. Frese, H. Ikeda, N. Haynes, E. Cretney, H. Yagita, N. Sueyoshi, Nobuhiro Sato, Y. Nakanuma, M. Smyth, K. Okumura (2008)
Death receptor 5 mediated-apoptosis contributes to cholestatic liver diseaseProceedings of the National Academy of Sciences, 105
-
Amith Panner, C. James, M. Berger, R. Pieper (2005)
mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme CellsMolecular and Cellular Biology, 25
-
C. Mitsiades, S. Treon, N. Mitsiades, Yoshihito Shima, P. Richardson, R. Schlossman, T. Hideshima, K. Anderson (2001)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.Blood, 98 3
-
E. Varfolomeev, H. Maecker, Darcie Sharp, D. Lawrence, M. Renz, D. Vučić, A. Ashkenazi (2005)
Molecular Determinants of Kinase Pathway Activation by Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand*Journal of Biological Chemistry, 280
-
Yigong Shi (2004)
Caspase activation, inhibition, and reactivation: A mechanistic viewProtein Science, 13
-
J. Mongkolsapaya, J. Grimes, N. Chen, Xiao-ning Xu, D. Stuart, E. Jones, G. Screaton (1999)
Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiationNature Structural Biology, 6
-
R. Rosato, J. Almenara, Yun Dai, S. Grant (2003)
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.Molecular cancer therapeutics, 2 12
-
E. Saulle, A. Petronelli, L. Pasquini, E. Petrucci, G. Mariani, M. Biffoni, G. Ferretti, G. Scambia, P. Benedetti‐Panici, F. Cognetti, R. Humphreys, C. Peschle, U. Testa (2007)
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosisApoptosis, 12
-
M. MacFarlane, N. Harper, R. Snowden, M. Dyer, Georgina Barnett, J. Pringle, Gerry Cohen (2002)
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemiaOncogene, 21
-
P. Secchiero, A. Gonelli, E. Carnevale, D. Milani, A. Pandolfi, D. Zella, G. Zauli (2003)
TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK PathwaysCirculation: Journal of the American Heart Association, 107
-
N. Finnberg, Andres Klein-Szanto, W. El-Deiry (2008)
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.The Journal of clinical investigation, 118 1
-
E. Bremer, D. Samplonius, Linda Genne, M. Dijkstra, B. Kroesen, L. Leij, W. Helfrich (2005)
Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR*Journal of Biological Chemistry, 280
-
S. Hinz, A. Trauzold, L. Boenicke, C. Sandberg, S. Beckmann, E. Bayer, H. Walczak, H. Kalthoff, H. Ungefroren (2000)
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosisOncogene, 19
-
D. Merino, N. Lalaoui, Alexandre Morizot, P. Schneider, E. Solary, O. Micheau (2006)
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2Molecular and Cellular Biology, 26
-
A. Pathil, S. Armeanu, S. Venturelli, P. Mascagni, T. Weiss, M. Gregor, U. Lauer, M. Bitzer (2006)
HDAC inhibitor treatment of hepatoma cells induces both TRAIL‐independent apoptosis and restoration of sensitivity to TRAILHepatology, 43
-
E. Bremer, D. Samplonius, L. Genne, M. Dijkstra, B. Kroesen, L. Leij, W. Helfrich
Simultaneous inhibition of EGFR signaling and enhanced activation of TRAIL-R-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. -
S. Kelley, A. Ashkenazi (2004)
Targeting death receptors in cancer with Apo2L/TRAIL.Current opinion in pharmacology, 4 4
-
A. Ashkenazi, R. Pai, S. Fong, Susan Leung, David Lawrence, S. Marsters, Christine Blackie, Ling Chang, Amy McMurtrey, Andrea Hebert, L. Deforge, I. Koumenis, D. Lewis, Louise Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, R. Schwall (1999)
Safety and antitumor activity of recombinant soluble Apo2 ligand.The Journal of clinical investigation, 104 2
-
E Varfolomeev, JW Blankenship, SM Wayson (2007)
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosisCell, 131
-
A. Grosse‐Wilde, O. Voloshanenko, S. Bailey, G. Longton, Uta Schaefer, Andreea Csernok, G. Schütz, E. Greiner, C. Kemp, H. Walczak (2008)
TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.The Journal of clinical investigation, 118 1
-
A. Joy, C. Beaudry, N. Tran, Francisco Ponce, D. Holz, T. Demuth, M. Berens (2003)
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosisJournal of Cell Science, 116
-
G. Pan, Jian Ni, Ying-Fei Wei, Guo-liang Yu, Reiner Gentz, V. Dixit (1997)
An antagonist decoy receptor and a death domain-containing receptor for TRAIL.Science, 277 5327
-
R. Koschny, H. Walczak, T. Ganten (2007)
The promise of TRAIL—potential and risks of a novel anticancer therapyJournal of Molecular Medicine, 85
-
A. Lahm, A. Paradisi, D. Green, G. Melino (2003)
Death fold domain interaction in apoptosisCell Death and Differentiation, 10
-
S. Shankar, T. Singh, R. Srivastava (2004)
Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanismsThe Prostate, 61
-
V. Snell, K. Clodi, Shourong Zhao, R. Goodwin, E. Thomas, S. Morris, M. Kadin, F. Cabanillas, M. Andreeff, A. Younes (1997)
Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignanciesBritish Journal of Haematology, 99
-
T. Ganten, R. Koschny, T. Haas, J. Sykora, M. Li‐Weber, K. Herzer, H. Walczak (2005)
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAILHepatology, 42
-
Fiona Kimberley, G. Screaton (2004)
Following a TRAIL: Update on a ligand and its five receptorsCell Research, 14
-
E. Petrucci, L. Pasquini, A. Petronelli, E. Saulle, G. Mariani, R. Riccioni, M. Biffoni, G. Ferretti, Pieluigi Benedetti-Panici, F. Cognetti, G. Scambia, R. Humphreys, C. Peschle, U. Testa (2007)
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.Gynecologic oncology, 105 2
-
C. García-echeverría, W. Sellers (2008)
Drug discovery approaches targeting the PI3K/Akt pathway in cancerOncogene, 27
-
D. Camidge, R. Herbst, M. Gordon, S. Eckhardt, R. Kurzroc, B. Durbin, J. Ing, J. Sager, D. Mendelson (2007)
A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer, 25
-
P Secchiero, E Melloni, F Corallini (2008)
TRAIL promotes migration of human bone marrow multipotent stromal cellsStem Cells, 26
-
J. Sparano, S. Moulder, Aslamuzzaman Kazi, L. Vahdat, Tianhong Li, C. Pellegrino, P. Munster, M. Malafa, David Lee, S. Hoschander, U. Hopkins, D. Hershman, J. Wright, S. Sebti (2006)
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 19
-
P. Lorusso, D. Hong, E. Heath, R. Kurzrock, Ding Wang, M. Hsu, L. Goyal, J. Wiezorek, C. Storgard, R. Herbst (2007)
First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumorsJournal of Clinical Oncology, 25
-
S. Wiley, K. Schooley, P. Smolak, W. Din, Changwei Huang, J. Nicholl, G. Sutherland, T. Smith, C. Rauch, Craig Smith, R. Goodwin (1995)
Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity, 3 6
-
A. Trauzold, D. Siegmund, B. Schniewind, Bence Sipos, Jan-Hendrik Egberts, D. Zorenkov, D. Emme, C. Röder, Holger Kalthoff, Harald Wajant (2006)
TRAIL promotes metastasis of human pancreatic ductal adenocarcinomaOncogene, 25
-
S. Petersen, Lai Wang, Asligul Yalcin-Chin, Lin Li, M. Peyton, J. Minna, P. Harran, Xiaodong Wang (2007)
Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.Cancer cell, 12 5
-
F. Greco, P. Bonomi, J. Crawford, K. Kelly, Y. Oh, W. Halpern, Larry Lo, G. Gallant, J. Klein (2008)
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.Lung cancer, 61 1
-
Hao Wu, J. Tschopp, Su‐Chang Lin (2007)
Smac Mimetics and TNFα: A Dangerous Liaison?Cell, 131
-
M. Romagnoli, Grégoire Desplanques, S. Maïga, S. Legouill, M. Dréano, R. Bataille, S. Barillé-Nion (2007)
Canonical Nuclear Factor κB Pathway Inhibition Blocks Myeloma Cell Growth and Induces Apoptosis in Strong Synergy with TRAILClinical Cancer Research, 13
-
M. Taniai, A. Grambihler, H. Higuchi, N. Werneburg, S. Bronk, Daniel Farrugia, S. Kaufmann, G. Gores (2004)
Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma CellsCancer Research, 64
-
F. Kischkel, David Lawrence, A. Chuntharapai, P. Schow, K. Kim, A. Ashkenazi (2000)
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.Immunity, 12 6
-
L. Belyanskaya, A. Ziogas, S. Hopkins‐Donaldson, S. Kurtz, H. Simon, R. Stahel, U. Zangemeister‐Wittke (2008)
TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.Lung cancer, 60 3
-
A. Tolcher, M. Mita, N. Meropol, M. Mehren, A. Patnaik, K. Padavic, M. Hill, T. Mays, T. McCoy, N. Fox, W. Halpern, A. Corey, R. Cohen (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 11
-
A. Krueger, I. Schmitz, S. Baumann, P. Krammer, S. Kirchhoff (2001)
Cellular FLICE-inhibitory Protein Splice Variants Inhibit Different Steps of Caspase-8 Activation at the CD95 Death-inducing Signaling Complex*The Journal of Biological Chemistry, 276
-
E. Varfolomeev, Marcus Schuchmann, V. Luria, N. Chiannilkulchai, Jacques Beckmann, I. Mett, Denis Rebrikov, V. Brodianski, O. Kemper, O. Kollet, T. Lapidot, Dror Soffer, T. Sobe, K. Avraham, T. Goncharov, H. Holtmann, P. Lonai, D. Wallach (1998)
Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally.Immunity, 9 2
-
Henry Lynch, C. Boland, M. Rodriguez-Bigas, C. Amos, J. Lynch, Patrick Lynch (2007)
Who should be sent for genetic testing in hereditary colorectal cancer syndromes?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 23
-
H. Walczak, Robert Miller, K. Ariail, B. Gliniak, T. Griffith, M. Kubin, Wilson Chin, Jon Jones, A. Woodward, Tiep Le, Craig Smith, P. Smolak, R. Goodwin, C. Rauch, J. Schuh, D. Lynch (1999)
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 5
-
James Herman, Howard Adler, Estuardo Aguilar-Cordova, Augusto Rojas-Martinez, S. Woo, T. Timme, Thomas Wheeler, Thomas Wheeler, Timothy Thompson, P. Scardino (1999)
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.Human gene therapy, 10 7
-
Hongxiu Li, Xin Lin (2008)
Positive and negative signaling components involved in TNFα-induced NF-κB activationCytokine, 41
-
M. Hornstein, M. Hoffmann, Adrian Alexa, M. Yamanaka, Mirko Müller, V. Jung, J. Rahnenführer, W. Schulz (2008)
Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.Cancer genomics & proteomics, 5 2
-
X. Volkmann, U. Fischer, M. Bahr, M. Ott, F. Lehner, M. MacFarlane, G. Cohen, M. Manns, K. Schulze-Osthoff, H. Bantel (2007)
Increased hepatotoxicity of tumor necrosis factor–related apoptosis‐inducing ligand in diseased human liverHepatology, 46
-
Lin Li, R. Thomas, Hidetaka Suzuki, J. Brabander, Xiaodong Wang, P. Harran (2004)
A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell DeathScience, 305
-
G. Suntharalingam, M. Perry, S. Ward, S. Brett, A. Castello-Cortes, Michael Brunner, N. Panoskaltsis (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.The New England journal of medicine, 355 10
-
G. Roué, P. Pérez-Galán, M. López-Guerra, N. Villamor, E. Campo, D. Colomer (2007)
Selective Inhibition of IκB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level1The Journal of Immunology, 178
-
T. Griffith, E. Broghammer (2001)
Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus.Molecular therapy : the journal of the American Society of Gene Therapy, 4 3
-
M. Degli-Esposti, W. Dougall, P. Smolak, Jennifer Waugh, Craig Smith, R. Goodwin (1997)
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.Immunity, 7 6
- Publisher
- Springer Journals
- Copyright
- Copyright © 2009 by Springer Science+Business Media, LLC
- Subject
- Biomedicine; Virology ; Biochemistry, general; Oncology ; Cell Biology; Cancer Research
- ISSN
- 1360-8185
- eISSN
- 1573-675X
- DOI
- 10.1007/s10495-009-0321-2
- pmid
- 19194800
- Publisher site
- See Article on Publisher Site
Abstract
Inducing apoptosis has become an important approach in the development of new anti-cancer treatments. Tumour necrosis factor apoptosis inducing ligand (TRAIL) based therapies have emerged as one of the most promising examples of this as they selectively induce apoptosis in tumour cells. However, many primary tumours are inherently resistant to TRAIL-mediated apoptosis and require additional sensitisation. Here we review apoptotic and non-apoptotic TRAIL-signalling, and the therapeutic effects of TRAIL-based treatments both as monotherapy and in combination with sensitising agents.
Journal
Apoptosis – Springer Journals
Published: Feb 5, 2009